Trial Profile
A Phase 1a/1b, First-in-human, Open-label Study of Escalating Doses of VE303 in Healthy Adult Volunteers With or Without Vancomycin Pre-treatment to Evaluate Safety, Dosing, and Pharmacodynamics
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2022
Price :
$35
*
At a glance
- Drugs VE 303 (Primary) ; Vancomycin
- Indications Clostridium difficile infections
- Focus Adverse reactions; First in man
- Sponsors Vedanta Biosciences
- 13 Apr 2022 Results presented in a Vedanta Biosciences Media Release.
- 13 Apr 2022 According to a PureTech Health media release, data from this trial published in Cell Host & Microbe paper.
- 13 Apr 2022 Results presented in the PureTech Health Media Release.